Targeted Genetics Advances Its Manufacturing Leadership; Additional Manufacturing Capabilities Reported at Scientific Meeting
02 Juin 2006 - 2:00PM
Business Wire
Targeted Genetics Corporation (Nasdaq:TGEND) is reporting new
developments in its portfolio of AAV manufacturing capabilities at
the American Society of Gene Therapy (ASGT) 2006 Annual Meeting.
One advance, reported yesterday afternoon in a poster, titled
"Clearance of Helper Adenovirus by an AAV1 Clinical Vector
Manufacturing Process" (Abstract #312), describes a robust method
for producing adeno-associated virus type 1 (AAV1) vectors. The
other, which will be presented today in a poster, titled "Improving
the Stability of Ad-AAV Hybrid Vectors" (Abstract #499), enables
another proprietary, scalable AAV manufacturing process that may be
applicable to commercial production. "Targeted Genetics' leadership
in designing and manufacturing AAV-based products is a defining
core competency for our company, and one that continues to generate
new product and revenue opportunities," said H. Stewart Parker,
president and chief executive officer at Targeted Genetics. "Our
ongoing innovation of proprietary manufacture of AAV vectors of
high purity raises industry standard for manufacturing AAV-based
products using commercially relevant processes. This strengthens
our ability to commercialize novel therapies, enhances our
competitive position and establishes us as the partner of choice
for companies seeking to access AAV development and manufacturing
capabilities." Abstract #312 describes a process for large-scale
manufacturing of vectors with AAV type 1 (AAV1) capsid proteins.
AAV1 vectors, and other AAV vectors engineered to produce AAV1
capsid proteins may possess advantageous properties in some
clinical settings compared with the AAV2 vectors that have been
evaluated in clinical trials to date. The process also enables the
effective and robust removal of "helper" viruses used in the
production of AAV vectors. The use of multiple separation
techniques removes helper virus from the vector preparation and a
robust heat inactivation step disables any remaining helper virus
without affecting the activity of AAV vectors. This method allows
for removal of helper virus in quantities that are significantly
greater than the amount of helper virus used in the manufacturing
process. Abstract #499 describes a scaleable adenovirus (Ad)-AAV
hybrid process of manufacturing AAV. In this method, a hybrid virus
that contains AAV sequences, Ad sequences and a gene of choice is
used in the manufacturing process of AAV vectors. Modifications of
the AAV construct have been made to improve the stability of the
Ad-hybrid virus, making this process more relevant for commercial
scale applications. About Targeted Genetics Targeted Genetics
Corporation is a biotechnology company committed to the development
and commercialization of innovative, targeted molecular therapies
for the prevention and treatment of inflammatory arthritis,
HIV/AIDS and other acquired and inherited diseases with significant
unmet medical need. Targeted Genetics uses its considerable
knowledge and capabilities in the development and manufacturing of
gene delivery technologies to advance a diverse product development
pipeline. Its product development efforts target inflammatory
arthritis, HIV/AIDS, congestive heart failure, Huntington's
disease, and hyperlipidemia. To learn more about Targeted Genetics,
visit its website at www.targetedgenetics.com. Safe Harbor
Statement under the Private Securities Litigation Reform Act of
1995: This release contains forward-looking statements regarding
our intellectual property, research programs and clinical trials,
our product development and our potential development platforms
including AAV vectors and other statements about our plans,
objectives, intentions and expectations and other statements about
our plans, objectives, intentions and expectations. These
statements, involve current expectations, forecasts of future
events and other statements that are not historical facts.
Inaccurate assumptions and known and unknown risks and
uncertainties can affect the accuracy of forward-looking
statements. Factors that could affect our actual results include,
but are not limited to, results of animal research are not
necessarily indicative of results in humans, the timing, nature and
results of our research, potential development of alternative
technologies or more effective products by competitors, our ability
to obtain and maintain regulatory or institutional approvals, our
ability to obtain, maintain and protect our intellectual property
and our ability to raise capital when needed, as well as other risk
factors described in Item 1A. Risk Factors in our report on Form
10-K for the year ended December 31, 2005, and updated in Item 1A.
Risk Factors in our Form 10-Q for the quarter ended March 31, 2006.
You should not rely unduly on these forward-looking statements,
which apply only as of the date of this release. We undertake no
duty to publicly announce or report revisions to these statements
as new information becomes available that may change our
expectations.
Targeted Genetics (NASDAQ:TGEND)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
Targeted Genetics (NASDAQ:TGEND)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024
Real-Time news about Targeted Genetics Corp (NASDAQ): 0 recent articles
Plus d'articles sur Targeted Genetics Corporation